# Panel 4: Marica Ferri (EUDA), "EU Strategies for Industry-Academia Partnership for Innovations"

**Channel:** International Society of Addiction Medicine (ISAM)
**Source:** https://www.youtube.com/watch?v=2RR24uacP3M
**Transcript page:** https://www.withtranscript.ai/video/2RR24uacP3M

## Chapters

- 0:04 — Introducing the EU Drugs Agency
- 3:25 — Current Drug Trends and Integrated Responses
- 7:46 — Innovation Needs in Treatment Services
- 11:47 — New Data on Youth and Behavior
- 13:29 — Continuity of Care and Research Priorities

## Transcript

**[0:04]:** Welcome to the global addiction therapeutics innovation day. Last but not least, um I have the pleasure of introducing MA Ferry who's the head of health and social sector of the newly formed EU drug agency. Most of you would know this agency as the European Monitoring Center for Drug and Drug Abuse, EMCDA. We're in Hamburg. We're in Europe. And we thought it would be um opportune to talk about the potential opportunities, the vision and the fact that this is an intergovernmental organization that has committed itself to provide a service which is quite exciting but also challenging. So Marica please.

**[1:04]:** Thank you very much for the invitation. I don't know if I can find my slides. Um I suspect the title of my lecture promise more than I will be able to do to deliver but uh luckily you are very tired so you will appreciate if I will be brief and quite vague. So as uh Alexander said before we are the European Union Drugs Agency. previously called European Monitoring Center for Drugs and Drug Addiction. Thank you very much. And uh no conflict of interest, glorified public servant as you said before. Um our agency was renamed last year in July. We are we are celebrating our first anniversary next month. And with this uh rename and a new mandate, we have been given new tasks and new challenges. Um the general idea is that we should be able to identify threats and to help the countries to put in practice some uh responses.

**[2:18]:** In this sense, we moved from what we did before which was evidence dissemination. I come from the concrete collaboration. So systematic reviewing of evidence and then dissemination of statement for action. Now we are asked to provide recommendations. So an increased in responsibility. In the same way sharing knowledge becomes something like assessment of outcomes. So not only saying what is evidence base but also what are the results and how should we implement more to obtain that results. So we move from what was called training to competence development with the idea of being able to prove that through our training and knowledge sharing people is more able to do what is called to do. And then the most challenging part that is the collaboration with the civil society organizations that as you know are well organized and and and want to be part of decision making in in this area.

**[3:25]:** what we see in this moment. Uh next month we will publish our new European drug report. Uh I cannot disclose too much is still embargoed but general uh picture what we see is an evolving as you can imagine uh situation very very fast from the covid-19 to now with new and unexpected challenges. So we have the new substances coming out uh quite often important shifting in patterns of drugs use. We still have the problem of opioid dependence of course but especially the younger generation is showing unexpected new behaviors and then the globalization of the elicit market using at best the new technology to reaching out different uh groups. And additionally, as we all are witnessing, there is a change in the political discourse that is challenging the way we have seen drugs related issues up to now and is really threatening the base of our society and the

**[4:35]:** way we respond to people with problems and we use of substances. So one of the changes in our agency that more closely affect our work is having put all the health and social responses in one sector and this is the sector that I share with a colleague here in in the room you will listen in the next days Charlotte Mitchell. So what does this imply has an effect because if there is one uh truth in our field is that there are no single interventions that have the power to resolve the situation. You cannot have the medical treatment that works per se if you don't have harm reduction interventions that are able to help the ones that are dropped out. You cannot have effective treatment if you don't have social reintegration measures to help the ones that are trying to quit their use of substances. So in in one sense although it's a bigger challenge for us is also a great opportunity to work together to make sure that the new for example investigations the new research enters into a global framework where also our

**[5:54]:** political counterpart cannot cherrypicking and say okay we like prevention and we want abstinenceoriented interventions because we know that is a global problem, a complex problem and needs a complex solution if ever solution we can say. Where are we uh investing just to use a business terminology not only in terms of resources uh but also in terms of time and commitment. We try to provide a more comprehensive training and capacity building program. We have an e-learning platform that we are developing and then we are trying to identify curricula also getting them from outside Europe and and organizations bearing in mind the vision that we have. So we don't enter into specific training for academia for example but we are very interested on those training that embrace larger group of professionals and then we are looking into quality standards for systems and for services empowering people working in the field to set their objectives and to measure their results towards there.

**[7:15]:** So why are we so interested in being here today as observers in this innovation day? Because this reflects exactly our commitment to learning, exchanging knowledge, and strengthening our collective responses to drugrelated challenges in the broader possible sense, including drugs related violence, including genderbased violence that sometimes is enhanced by the use of substances.

**[7:46]:** What are the new needs and the priorities we need to cover with innovation? We said before shift in substance use partners rise for example in psycho stimulants use is a phenomenon that we are observing in all Europe and for which we don't have I I'm very thankful for shaka before say when you have someone under the effect of psychoso stimulants before you can apply the psychosocial interventions for which we have evidence sorry we need to have something that that enables stabilization of of patients. So this is why thank you very much. This is why we need our collaboration. It's more difficult to attract clients and to keep them in treatment. We know that thank you very much. People with psycho stimulants uh disorders quit treatment very often. they they don't feel hooked into treatment as are opioids, people who use opioids because of the effectiveness of methadone.

**[8:54]:** There is a growing use of concern, a growing concern about the use of ketamine. Someone mentioned ketamine before, especially among young people and there is a a longer lapse before the problem is evident. So the traditional opioid focused services especially in Europe are not equipped to answer the problems of these type of people. So we need to train the medical staff to identify new substances related issues the ones that are not so self-evident as it was historically with people using opioids and developed tailor interventions to engage and retain affected individuals. Again in the broader sense is not only the person who uses substances it's the families the children all the community we I said it before we have a different political context we need to take this into consideration it's not sufficient to say they are wrong there is a radical shift in the societal attitudes towards substance use and related interventions and there is a significant reduction in the funds.

**[10:08]:** So what are the challenges for the frontline workers? Improve and measure the quality of their interventions. Now we need to side people and to say to be able to defend their work to say even small differences are better than nothing and we need to help them to do that. So demonstrate effectiveness to ensure service continuity. Small example if we have as it is the case in Europe we have court of opioid users that have reached a certain age of course they are a problem because they start having somatic problems on top of the problems generated by drug but this is a big success my generation people using opioids died one year after the diagnosis of HIV so we need to change the narrative to make this that is known own in this in this context we need to make it communic communicate it to um policy makers decision makers so persuade the shism makers that without such intervention society would face a greater harm there is a lot of concern in Europe about

**[11:20]:** drugs related violence we had a conference in November last year you may have known that there have been shootings in in Brussels in in Sweden Then and this is something that has uh called the attention. We need to to to to to talk about this. We need to show that there are ways of reduces the reduces this level of violence.

**[11:47]:** So what we see just to to share with you some new data sorry there is an overlapping there in the in the outline. The Espad uh survey in the schools showing data for the last 30 years shows that in fact younger generation are using less substances. This is a good news but this also means that we are not equipped to answer their problems because we see that for example girls are developing problems in comparison with boys as it wasn't the case before. There is an increase in use of medicines. There is an increase of addiction to technology. We know this. But for example, our agency has no means of treating this these issues. But we know that when we talk about health and behavior things comes all together. You cannot say okay we help you for alcohol but we don't consider addiction to the telephone.

**[12:48]:** We cannot. If we want to be evidence-based and effective, we need to see everything together. We work and we are privileged in this. We work with the European framework. We have the European drug strategy that reflect the vision of all the countries and the civil society organizations. So we start already. Okay. Thank you very much. I promise I was short and I wasn't. Um we we start already with the idea that we need to be health centered, human rightsbased, evidence-based, comprehensive and integrated and that treatment need to be accessible and available.

**[13:29]:** So I don't I don't want to go too too too much in into detail but the continuity of care is something that is absolutely fundamental as well as the ethical and professional attitude of people who has chosen to work in this field. So I don't want to uh repeat the the mantra about health and social interventions this all these doors the idea is to say we have a target population what we need to do is to overcome because you know that also internal in in the field there are discussion people working in in prevention doesn't like the ones working in harm reduction and altogether against treatment etc etc we cannot cannot afford this any longer. We need to think of interventions like series of doors helping people to enter somewhere in their trajectory as ready as they are in this moment and go on proposing to make sure that they can reach their full potential

**[14:33]:** to be uh to to be integrated in the in the society just two initiatives. So I didn't talk really about in industry and and and and research two initiatives about from the European Union that we think are very important and can make the difference. Once one is old is called sorry um health space and Charlotte is following after the covid it was clear that we need to share data. Of course, there are all the limitations of the data protection that are even more important in our environment. Still, one recommendation is these interventions are for the medical field. Please researchers make sure that these opportunities are used also in our field. If we could measure the outcomes of the interventions directly from the clinical records, our uh knowledge would change dramatically and we need to do it. Another thing is a very recent you have read everywhere.

**[15:44]:** It's not yet clear to me what's in this package but this attempt to make Europe interesting for researchers coming from other side of the world. I don't I'm not naming any country. Still again look into it. There is a lot of money. Make sure that drug addiction is considered into this big package because otherwise will be disregarded and is not in our interest. Organized by International Society of Addiction Medicine sponsors and co-organizers Senray Indivir Spark Biomed Salofa Ethoparm University of Minnesota European Union Drugs Agency UK Office for Life Sciences
